Altcoin Season Imminent After Taking it ‘On the Chin’ Since March – Next Crypto to Watch?
RealVision’s Chief Crypto Analyst, Jamie Coutts, believes that an altcoin season might be imminent. He points out that altcoins have been trading lower since Bitcoin reached its all-time high in March.
The Bitcoin price hit an all-time high of $73,750.07 on March 14th, but it has slumped over 10% since then to $66,200.05.
In a recent X post , Coutts noted that “smaller-cap crypto assets have been taking it on the chin since the March high of this year.”
Coutts referenced data from Bitformance indicating that over the past 3 months, the Top 200 Equal Weight Index, which assigns weight equally to cryptocurrencies irrespective of market cap, fell by 33%.
This contrasted with the Market Cap Index, which declined by 12%, weighting cryptocurrencies based on their market capitalization.
This decline underscores weaker performance among smaller cryptocurrencies compared to those dominating the market cap index.
More recent Bitformance data also reveals a notable shift. The percentage of altcoins in the top 200 Marketcap-Weighted Index with a higher 90-day return than BTC dropped significantly from 49% to 10% since March 14th.
This indicates that an altcoin season is currently distant. Despite this, Coutts believes altcoins may be gearing up to present “some opportunities.”
“If this is a regular mid-cycle correction we are experiencing, which I believe is likely, then expect some opportunities to be had in the mid and small caps once the market settles.”
This “settling” was supported in a recent Bloomberg interview with Coinshares Advisor Meltem Demirors , citing recent market activity to be an indication of a “sideways summer” as the market consolidates.
This follows the uncertainty generated by the US Federal Reserve’s hawkish stance on inflation .
Keep Your Eye On AI For Altcoin Season
Notably, in a reply from an X user inquiring about AI crypto’s place in a potential altcoin season, Coutts proclaimed optimism, saying, “ I do genuinely see opportunity there.”
The inquiry questioned when AI hype will fully permeate into crypto. This follows Nvidia’s impressive Q1 earnings report, which caused AI-related stocks to surge. However, AI crypto did not mirror this trend, contrary to expectations among crypto traders.
The user also noted that high-potential AI projects seemed to be misunderstood or under-allocated relative to other non-AI crypto projects traditional AI-related assets.
Despite this optimism, Coutts has not named any particular opportunities pre-altcoin season. He claims that he is “still working through an asset selection approach.”
This New Low-Cap Gem Captures The AI Spotlight
Given that many prominent AI projects have already achieved multi-billion dollar market caps, it’s uncertain whether significant gains are still possible going forward, even though these projects may still be undervalued compared to other AI assets.
Therefore, traders seeking faster and bigger returns may find a strategic advantage in exploring newer low-cap meme coins set for explosive growth .
Enter WienerAI ($WAI), a new meme coin and AI companion cited to become “every crypto trader’s Best Friend.”
The meme coin market is over-saturated with Shiba Inu-themed coins boasting little to no real utility. Something which may credit Weiner AI’s (WAI) recent success, raising over $6 million in its presale so far.
Touted as a “Revolutionary AI Trading partner,” WienerAI is a digital companion that gives its owner user-friendly AI-enhanced trading advice , seamless swap functionality, and zero fees.
Around 20% of $WAI’s supply is for staking, and investors are currently earning a massive 188% APY, as per the project’s official website .
Follow the latest developments on Weiner AI’s X account .
Buy WienerAI Here
Disclaimer: Crypto is a high-risk asset class. This article is provided for informational purposes and does not constitute investment advice. You could lose all of your capital.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
